为促进本公司的可持续经营及发展，维护投资者的长期利益及使股东价值最大化，经综合考虑本公司目 前的经营状况，财务状况及未来发展前景，董事会决定于本公告日期至本公司下届股东周年大会结束 (届时购回授权将届满)或股东于本公司股东大会上撤销或更改授权期间，本公司将根据市场状况及购回 授权，动用最高总额港币壹亿元不时于公开市场上购回股份，每股股份的实际购回价格不得比股份于紧 接每次购回前五个交易日的平均收市价高出5%或以上。董事会认为，股份回购计划符合本公司及其股 东的整体最佳利益。 喜相逢集团(02473)发布公告，董事会拟根据于2025年6月18日举行之本公司股东周年大会上本公司股东 通过的决议案授予董事会的一般授权，以购回本公司股份的权力。根据购回授权，本公司获准购回于股 东周年大会日期已发行股份总数最多10%的本公司股份，即最多1.55亿股股份。 ...

Core Insights - NetEase Cloud Music (09899) reported a revenue of approximately 7.759 billion yuan for 2025, with a gross profit of about 2.77 billion yuan, reflecting a year-on-year growth of 3.3% [1] - The annual profit reached approximately 2.746 billion yuan, marking a significant year-on-year increase of 75.4%, while the adjusted net profit was around 2.86 billion yuan, up by 68.2% [1] Group 1: User Engagement and Community Development - The company continues to expand and deepen its music-oriented community ecosystem, leading to growth in user scale and activity [1] - Daily active users (DAU) as a percentage of monthly active users (MAU) maintained above 30%, showing steady improvement compared to 2024 [1] - The average daily listening time for mobile users has also increased, indicating enhanced user engagement [1] Group 2: Content Strategy and Partnerships - The company has enriched its copyright music reserves and actively promoted original Chinese music, creating a diverse and unique content library [1] - In 2025, the company introduced content from Korean labels to supplement its Chinese music library, adding film soundtracks and variety show music [1] - The company deepened collaborations with labels for content promotion and music-centric activities, while its independent musician ecosystem continued to thrive [1] Group 3: Product Innovation and User Experience - The company prioritized user needs and focused on innovating music discovery and listening experiences [2] - In 2025, the core product framework was upgraded to enhance visual appeal and better meet diverse music discovery preferences [2] - The launch of the self-developed AI generative recommendation model "Climber" and features like Automix and "Shen Guang Player" provided an immersive audio-visual experience [2] Group 4: Revenue and Profitability - The monetization capability centered around music continued to achieve steady growth, with membership subscription revenue increasing by 13.3% due to a rise in membership scale [2] - The growing membership scale demonstrated stronger user stickiness, with improved retention and activity rates [2] - The company's gross margin reached 35.7% in 2025, significantly up from 33.7% in 2024, with operating profit increasing by 38.5% due to business scale growth and improved online music commercialization capabilities [2]

董事会研究发现，上述五个国家和地区对专业化、高品质产后康复服务存在显著且未被充分满足的需 求。该等需求具备良好的商业化前景，且董事会观察到当地市场已出现本地人设立的月子中心品牌，而 且设立的本地月子中心品牌，均得到非常好的市场反馈。本次拓展旨在把握当前关键机遇窗口，率先建 立品牌影响力与市场地位。 3.验证标准化运营体系：本次的多国同步拓展，验证了本集团在服务流程、运营管理及人才培训方面已 构建出一套成熟、可靠且可对外大规模输出的标准化体系。这将有助于本集团在未来以更高的效率开拓 新市场。 董事会相信，本次拓展符合本集团的长远发展战略，将为本集团带来新的增长动力。未来，本集团将继 续聚焦全球一线高端市场，通过高标准化的服务和极致的客户体验，满足全球家庭对专业化产后护理服 务日益增长的需求，为本公司股东创造长远而稳定的价值。 圣贝拉(02508)发布公告，本集团的全球战略拓展计划近期取得重大进展，将拓展至美国东部、英国、 法国、泰国及澳大利亚，并将于该五个国际枢纽地区设立新的服务网点，目前本集团已经与美国纽约、 英国伦敦、法国巴黎、泰国曼谷等城市的合作伙伴达成战略签约。 董事会认为，此次战略性拓展将为本集团带来 ...

香港信贷(01273)发布公告，于2026年2月11日，香港信贷(作为贷款人)与客户J孙喆楠、客户K孙小杰及 客户L林惜文(统称为借款人)订立新贷款协议。根据新贷款协议，香港信贷已同意向借款人授出本金金 额为1300万港元的新贷款。 ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) has participated in the procurement process for the continuation of drug selection following the expiration of the national organized procurement agreements, with 13 products, including Fumarate Bisoprolol Tablets and Etoricoxib Tablets, proposed for selection in this round of procurement [1] Group 1 - The procurement process is organized by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce drug prices while providing greater choice for medical institutions [1] - The selection of 13 products by the company, despite some price reductions compared to original sales prices, is expected to help maintain market share and enhance drug accessibility if contracts are signed and executed [1] - The procurement aims to ensure continuity in clinical medication and reduce the risks associated with drug switching due to organized procurement [1]

TAI PING CARPET(00146)公布截至2025年12月31日止6个月中期业绩，收益约3.09亿港元，同比增长 0.36%;公司拥有人应占溢利1968.6万元，同比减少9.27%;每股溢利9.28港仙。 ...

国际家居零售(01373)发布公告，于2026年2月11日斥资10.8万港元回购15万股。 ...

该信息由智通财经网提供 智通财经APP讯，十月稻田(09676)发布公告，于2026年2月11日，该公司斥资424.97万港元回购48.69万 股股份，每股回购价8.44-8.91港元。 ...

Core Viewpoint - The strategic cooperation agreement between Zhongsheng Beikong Biotechnology (08247) and Xiaoshou Medical aims to enhance the capacity of grassroots medical services and promote the distribution of quality medical resources [1] Group 1: Capital and Strategic Collaboration - The company plans to make a strategic investment in Xiaoshou Medical to establish a long-term stable partnership and explore innovative development models in the grassroots medical market [2] Group 2: Business and Resource Complementation - The company will leverage its advantages in in vitro diagnostics (IVD) products and R&D capabilities, combined with Xiaoshou Medical's nationwide grassroots medical channel network and digital platform, to deliver biochemical, immunological, and POCT products directly to grassroots medical institutions [3] - A joint working group will be established to enhance data insights, product development, and supply chain optimization while developing customized products and "smart testing solutions" suitable for grassroots medical scenarios [3] Group 3: Ecosystem and Value Co-Creation - The collaboration will integrate various resources such as equipment, reagents, operations, and data to provide one-stop testing service solutions for regional medical communities and chain clinics, thereby improving the overall testing capabilities and operational efficiency of grassroots medical institutions [4] - The cooperation will be implemented in phases, starting with strategic pilot verification and gradually expanding to large-scale implementation, while exploring deeper collaboration at the industrial and capital levels [4] - The board believes that this strategic cooperation will help the company integrate quality R&D capabilities with digital channel resources, accelerating the penetration of products and services into grassroots medical institutions, aligning with national initiatives to enhance the grassroots medical system and the "Healthy China" strategy [4]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval was granted to Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd. [1] - The company has invested approximately RMB 1.5 million in research and development for Tamsulosin hydrochloride [1] - The drug is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] Group 2: Regulatory and Market Implications - The approval indicates that the raw material meets the regulatory requirements for domestic drug registration, allowing it to be sold in the domestic market [1] - This experience will be valuable for the company in future raw material drug applications [1] - The approval is not expected to have a significant impact on the company's current operating performance [1]